CCRP CERTIFICATION EXAM PREP 2026 Updated
Practice Questions — Comprehensive Clinical Research
Professional Review Detailed Explanations • Verified
Answers • Complete Success Workbook
DOMAIN 1: RESEARCH STUDY START-UP (Questions 1–40)
Question 1
According to ICH GCP, what is the primary responsibility of the Investigator?
A) To ensure the study is financially viable
B) To conduct the trial in accordance with the protocol, GCP, and applicable
regulations
C) To monitor the trial data for accuracy
D) To provide all study supplies
Rationale: ICH GCP E6(R2) clearly defines the Investigator's primary
responsibility as conducting the trial in accordance with the signed Investigator
Agreement, the protocol, GCP, and applicable regulatory requirements. While data
monitoring and supply management are important, they are not the primary
responsibility of the Investigator.
Question 2
Which document is considered the foundation of modern research ethics and was
developed in response to the atrocities of World War II?
A) The Belmont Report
B) The Nuremberg Code
C) The Declaration of Helsinki
D) The Common Rule
Rationale: The Nuremberg Code (1947) was the first international code of
research ethics, established in response to Nazi medical experiments. It introduced
the concept of voluntary informed consent as essential. The Belmont Report (1979)
and Declaration of Helsinki (1964) built upon these principles.
,Question 3
What is the primary purpose of an Institutional Review Board (IRB)?
A) To approve study budgets
B) To protect the rights and welfare of human research subjects
C) To review scientific validity only
D) To select study investigators
Rationale: The IRB's primary purpose is to protect the rights and welfare of
human subjects. While IRBs do review scientific merit, their core function is
ethical oversight. Budget approval and investigator selection are not IRB
responsibilities.
Question 4
Under 21 CFR Part 50, what is the minimum age at which a subject can provide
legally effective informed consent for themselves?
A) 16 years
B) 18 years
C) 21 years
D) 25 years
Rationale: Under 21 CFR Part 50 (Protection of Human Subjects), the legal age of
consent is 18 years in most jurisdictions. Individuals under 18 require
parental/guardian permission and may provide assent depending on institutional
policy and state law.
Question 5
Which of the following is a required element of informed consent according to 21
CFR Part 50?
A) A statement that the study is approved by the FDA
B) A statement that participation is voluntary and refusal will not result in
penalty
C) The investigator's personal contact information
D) A guarantee of treatment if injury occurs
,Rationale: 21 CFR 50.25 requires that informed consent include a statement that
participation is voluntary, refusal to participate will involve no penalty, and the
subject may discontinue at any time. While some other elements may be included,
a guarantee of treatment is not required.
Question 6
What is the difference between a "Serious Adverse Event" (SAE) and an "Adverse
Event" (AE)?
A) SAEs are always expected; AEs are unexpected
B) SAEs result in death, are life-threatening, require hospitalization, or cause
disability
C) SAEs occur in the control group; AEs occur in the treatment group
D) There is no difference; the terms are interchangeable
Rationale: An SAE is any adverse event that results in death, is life-threatening,
requires inpatient hospitalization or prolongation of existing hospitalization, results
in persistent or significant disability/incapacity, or is a congenital anomaly/birth
defect. AEs are any untoward medical occurrences that do not meet these severity
criteria.
Question 7
Which regulatory document governs the protection of human subjects in research
conducted or supported by U.S. federal departments and agencies?
A) 21 CFR Part 11
B) 21 CFR Part 312
C) 45 CFR Part 46 (The Common Rule)
D) 21 CFR Part 812
Rationale: 45 CFR Part 46, also known as the Common Rule, governs the
protection of human subjects in research conducted or supported by U.S. federal
departments and agencies. 21 CFR Parts 11, 312, and 812 pertain to electronic
records, IND applications, and IDE applications, respectively.
, Question 8
What is the purpose of a Data Safety Monitoring Board (DSMB)?
A) To review the study budget
B) To monitor subject safety and study data during the trial
C) To recruit study subjects
D) To write the clinical study report
Rationale: A DSMB is an independent committee that monitors subject safety and
study data during a clinical trial. They can recommend early termination if safety
concerns or overwhelming efficacy are observed. They do not recruit subjects or
write study reports.
Question 9
Which of the following is TRUE regarding the Declaration of Helsinki?
A) It is a legally binding U.S. regulation
B) It is a statement of ethical principles for medical research involving human
subjects
C) It applies only to drug research
D) It was first published in 1979
Rationale: The Declaration of Helsinki is a statement of ethical principles for
medical research involving human subjects, developed by the World Medical
Association. It is not legally binding but has been incorporated into many
regulations and guidelines. It was first adopted in 1964.
Question 10
What is the role of the Sponsor in a clinical trial?
A) To obtain informed consent from subjects
B) To initiate, manage, and finance the clinical trial
C) To conduct the trial at the site
D) To review the trial for ethical compliance
Rationale: The Sponsor is the individual, company, or organization that initiates,
manages, and finances the clinical trial. The Investigator conducts the trial at the
site, and the IRB reviews for ethical compliance.
Practice Questions — Comprehensive Clinical Research
Professional Review Detailed Explanations • Verified
Answers • Complete Success Workbook
DOMAIN 1: RESEARCH STUDY START-UP (Questions 1–40)
Question 1
According to ICH GCP, what is the primary responsibility of the Investigator?
A) To ensure the study is financially viable
B) To conduct the trial in accordance with the protocol, GCP, and applicable
regulations
C) To monitor the trial data for accuracy
D) To provide all study supplies
Rationale: ICH GCP E6(R2) clearly defines the Investigator's primary
responsibility as conducting the trial in accordance with the signed Investigator
Agreement, the protocol, GCP, and applicable regulatory requirements. While data
monitoring and supply management are important, they are not the primary
responsibility of the Investigator.
Question 2
Which document is considered the foundation of modern research ethics and was
developed in response to the atrocities of World War II?
A) The Belmont Report
B) The Nuremberg Code
C) The Declaration of Helsinki
D) The Common Rule
Rationale: The Nuremberg Code (1947) was the first international code of
research ethics, established in response to Nazi medical experiments. It introduced
the concept of voluntary informed consent as essential. The Belmont Report (1979)
and Declaration of Helsinki (1964) built upon these principles.
,Question 3
What is the primary purpose of an Institutional Review Board (IRB)?
A) To approve study budgets
B) To protect the rights and welfare of human research subjects
C) To review scientific validity only
D) To select study investigators
Rationale: The IRB's primary purpose is to protect the rights and welfare of
human subjects. While IRBs do review scientific merit, their core function is
ethical oversight. Budget approval and investigator selection are not IRB
responsibilities.
Question 4
Under 21 CFR Part 50, what is the minimum age at which a subject can provide
legally effective informed consent for themselves?
A) 16 years
B) 18 years
C) 21 years
D) 25 years
Rationale: Under 21 CFR Part 50 (Protection of Human Subjects), the legal age of
consent is 18 years in most jurisdictions. Individuals under 18 require
parental/guardian permission and may provide assent depending on institutional
policy and state law.
Question 5
Which of the following is a required element of informed consent according to 21
CFR Part 50?
A) A statement that the study is approved by the FDA
B) A statement that participation is voluntary and refusal will not result in
penalty
C) The investigator's personal contact information
D) A guarantee of treatment if injury occurs
,Rationale: 21 CFR 50.25 requires that informed consent include a statement that
participation is voluntary, refusal to participate will involve no penalty, and the
subject may discontinue at any time. While some other elements may be included,
a guarantee of treatment is not required.
Question 6
What is the difference between a "Serious Adverse Event" (SAE) and an "Adverse
Event" (AE)?
A) SAEs are always expected; AEs are unexpected
B) SAEs result in death, are life-threatening, require hospitalization, or cause
disability
C) SAEs occur in the control group; AEs occur in the treatment group
D) There is no difference; the terms are interchangeable
Rationale: An SAE is any adverse event that results in death, is life-threatening,
requires inpatient hospitalization or prolongation of existing hospitalization, results
in persistent or significant disability/incapacity, or is a congenital anomaly/birth
defect. AEs are any untoward medical occurrences that do not meet these severity
criteria.
Question 7
Which regulatory document governs the protection of human subjects in research
conducted or supported by U.S. federal departments and agencies?
A) 21 CFR Part 11
B) 21 CFR Part 312
C) 45 CFR Part 46 (The Common Rule)
D) 21 CFR Part 812
Rationale: 45 CFR Part 46, also known as the Common Rule, governs the
protection of human subjects in research conducted or supported by U.S. federal
departments and agencies. 21 CFR Parts 11, 312, and 812 pertain to electronic
records, IND applications, and IDE applications, respectively.
, Question 8
What is the purpose of a Data Safety Monitoring Board (DSMB)?
A) To review the study budget
B) To monitor subject safety and study data during the trial
C) To recruit study subjects
D) To write the clinical study report
Rationale: A DSMB is an independent committee that monitors subject safety and
study data during a clinical trial. They can recommend early termination if safety
concerns or overwhelming efficacy are observed. They do not recruit subjects or
write study reports.
Question 9
Which of the following is TRUE regarding the Declaration of Helsinki?
A) It is a legally binding U.S. regulation
B) It is a statement of ethical principles for medical research involving human
subjects
C) It applies only to drug research
D) It was first published in 1979
Rationale: The Declaration of Helsinki is a statement of ethical principles for
medical research involving human subjects, developed by the World Medical
Association. It is not legally binding but has been incorporated into many
regulations and guidelines. It was first adopted in 1964.
Question 10
What is the role of the Sponsor in a clinical trial?
A) To obtain informed consent from subjects
B) To initiate, manage, and finance the clinical trial
C) To conduct the trial at the site
D) To review the trial for ethical compliance
Rationale: The Sponsor is the individual, company, or organization that initiates,
manages, and finances the clinical trial. The Investigator conducts the trial at the
site, and the IRB reviews for ethical compliance.
